Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 107Carcinoma, Renal Cell 74Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 35Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Carcinoma, Hepatocellular 14Colorectal Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

Sunitinib 1Robotic Surgical Procedures 1Laparoscopy 1Everolimus 1Conversion to Open Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neuroendocrine Tumors × Everolimus × Clear all
NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Novartis

Phase 4 Completed
61 enrolled 9 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡